Authors
Latest:
Dr. Manne on the Need for Novel Therapies in HCC Without Preserved Liver FunctionAshish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.
Latest:
Dr Vega on an Analysis of Outcomes with Axillary Surgery in Breast Cancer Post-Neoadjuvant ChemoRaymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.
Latest:
Treating Brain Metastases and the future of HER2+ mBCClosing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.
Latest:
Dr. Schjesvold on OCEAN Trial Takeaways With Melflufen in Relapsed/Refractory MyelomaFredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Pawlik on Advances in Management of mCRC With Liver MetastasesTimothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.
Latest:
Future Treatment Directions and Ongoing Trials in CLLMarc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.
Latest:
Dr Marquina on the Importance of Referring Patients With GIST to Specialized Sarcoma CentersGloria Marquina, MD, PhD, as well as the need to consider ongoing clinical trials for patients with gastrointestinal stromal tumors vs treatment with the current second-line standard-of-care agent sunitinib.
Latest:
Dr Lee on the Significance of the Tumor-Agnostic Approval of T-DXd for HER2+ Urothelial CancerJohn K. Lee, MD, PhD, discusses the significance of the tumor-agnostic approval of T-DXd specifically for patients with HER2-positive urothelial cancer.
Latest:
Dr. Barba on the Safety of Obecabtagene Autoleucel in Relapsed/Refractory B-ALLPere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Latest:
Sutherland on the Promise of CDK4 Inhibitors in Metastatic Breast CancerDiana Sutherland, NP, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.
Latest:
Dr Peng on the Efficacy of SHR-1701 Plus Chemotherapy in HER2– Gastric/GEJ CancerZhi Peng, MD, discusses a study of SHR-1701 vs placebo in combination with chemotherapy in the first-line management of HER2– gastric/GEJ adenocarcinoma.
Latest:
Dr Jain on the VERONA Study in Higher-Risk MDSAkriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.
Latest:
Breast Cancer Treatment: Sequencing With Antibody-Drug ConjugatesClinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.
Latest:
Perspectives on Treating CCA Moving ForwardA panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
Latest:
California Doctor Receives Northwestern Medicine’s First Combined Lung-Liver Transplant for Advanced Lung CancerGary Gibbon, MD, pulmonologist and allergist, visited Chicago for a first-of-its-kind transplant procedure, becoming the first person in the U.S. to receive a double-lung and liver transplant for advanced lung cancer.
Latest:
Dr. Marazzi on the Goals of Examining Topotecan in COVID-19 and CancerIvan Marazzi, PhD, discusses the goals for examining topotecan as a treatment for patients with COVID-19 and cancer in India and Brazil.
Latest:
Frontline Therapeutic Planning for Metastatic Renal Cell CarcinomaIn this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.
Latest:
Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian CancerBruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.
Latest:
Dr Cummings on Adjuvant Osimertinib in EGFR-Mutant NSCLCAmy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.
Latest:
Dr. Chern on Outcomes With PARP Inhibitors in Recurrent Ovarian CancerJing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.
Latest:
Dr Garrot on Lutetium Lu 177 Vipivotide Tetraxetan in Older Patients with MCRPCLouis Crain Garrot, MD, discusses the role of lutetium Lu 177 in older patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Mulcahy on the Design of the EPOCH Trial in mCRC With Liver MetastasesMary F. Mulcahy, MD, discusses the design of the phase 3 EPOCH trial in patients with metastatic colorectal cancer and liver metastases.
Latest:
Dr Fathi on Ziftomenib in R/R NPM1-Mutant AMLAmir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.
Latest:
Pebbles Fagan, Ph.D., MPH, Joins Leadership Team at UAMS Winthrop P. Rockefeller Cancer InstitutePebbles Fagan, Ph.D., MPH, has assumed the role of associate director for Cancer Prevention and Control for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences.
Latest:
Dr Tauro on the Rationale for Investigating ULK3 in Multiple MyelomaMarilena Tauro, PhD, discusses the investigation of ULK3 in patients with multiple myeloma.
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
How to Improve Care for LGBTQI+ Patients With CancerAs more and more people in the United States identify as lesbian, gay, bisexual, transgender, queer, intersex, or other sexual orientation or gender minority, the population of LGBTQI+ cancer survivors is becoming uniquely heterogeneous.
